Latest news with #aorticvalvereplacement
Free Malaysia Today
09-08-2025
- Health
- Free Malaysia Today
Welfare NGO seeks funds for teen's RM60,000 heart surgery
Muhammad Nur Amin Abdullah was diagnosed with a hole in his heart when he was five years old. (CCEP Foundation pic) PETALING JAYA : At 17, most teenagers are busy preparing for their SPM exams. But for Muhammad Nur Amin Abdullah, life carries an added weight – the uncertainty of living with a heart condition. Amin was five when he was diagnosed with a small opening in one of his heart valves. Despite having undergone surgery at the time, the hole grew larger as he grew older. More recently, his heart became swollen, causing him to tire easily and experience shortness of breath. Upon being referred to Institut Jantung Negara (IJN), he was told he needed an aortic valve replacement. As his situation was critical, Amin last month underwent the procedure that cost RM60,000 – a sum far beyond what his family can afford. That's when CCEP Foundation, an NGO that helps the poor, needy, deprived and underprivileged, stepped in to help. According to its CEO, Yvonne Yee, Amin was referred to them by IJN and the NGO issued a written commitment to the hospital to cover the surgery cost. FMT Lifestyle has verified the case with IJN. The procedure was successfully performed on July 19, and Amin was discharged from the hospital on July 28. Now, the NGO is appealing for the public's help to raise the funds. Family matters According to Yee, Amin's mother stays home to care for her family and depends only on her husband's monthly income of RM800, along with some aid from the welfare department. Amin's biological father passed away when he was in Standard Two. Amin with CCEP Foundation CEO Yvonne Yee. (CCEP Foundation pic) Amin, the second of seven siblings, has an older brother who had been involved in a road accident at age 10. This caused a bone misalignment that has never been operated on. Another brother, 16, is disabled. He, too, had been involved in an accident when he was younger, which led to bone problems. As the family couldn't afford treatment, he eventually lost his ability to walk. Amin's other siblings are aged 12, seven and six, while the youngest is only three months old. Amin lives with his mother, stepfather, siblings and grandparents in a small zinc-roofed wooden house. 'After learning about their living conditions, we decided to help Amin,' Yee said, adding that they began fundraising on July 28 and have raised almost RM20,000 as of press time. Education and ambition Yee describes Amin as a determined and positive young man. 'He understands that in order to change his family's difficult situation, he must first be healthy. 'He told us sincerely, 'I want to give my family a comfortable life.' A young person with such strong ideals and maturity truly deserves our support.' For Amin, education is the key to breaking the cycle of poverty. 'My ambition is to continue my studies in a university because I want to improve my family's future,' he said. Meanwhile, his mother Yana shared: 'He studies very hard, but he has fainted many times in school due to fatigue, as his classroom is on the fourth floor. Whenever he feels unwell, his teachers will call me to pick him up.' She added that Amin always tries his best not to miss school and to complete his homework as he will be sitting for SPM this year. If you wish to help, donations can be made directly to CCEP Foundation, RHB Bank account number 2621 9300 009 342. Please use the reference 'Nur Amin'. If you require a receipt, kindly send them a WhatsApp message. Learn more about CCEP Foundation here, or contact 03-7955 9999 / 010-279 8849.
Yahoo
14-07-2025
- Business
- Yahoo
JenaValve Announces First Patient Enrolled in ARTIST Randomized Controlled Trial (RCT) Evaluating the Trilogy™ System in Aortic Regurgitation (AR)
IRVINE, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, today announced that patient enrollment has begun in the ARTIST study, an RCT evaluating the safety and effectiveness of the Trilogy System compared to surgical aortic valve replacement (SAVR) in patients with AR. The study is now enrolling patients in both transcatheter and surgical arms with the first case being performed in Los Angeles, California at Cedars-Sinai Medical Center. ARTIST is designed to provide critical evidence for the treatment of moderate-to-severe and severe AR in patients that are not at high-risk for surgical aortic valve replacement and is the first ever randomized study comparing SAVR vs. transcatheter aortic valve replacement (TAVR) in AR patients. The company anticipates this study will help continue to elevate the versatility of the Trilogy System, following the outcomes achieved in AR patients that are at high surgical risk. 'It's incredibly rewarding to have enrolled and treated the first randomized patient in the ARTIST trial,' said Dr. Raj Makkar, MD, Cedars-Sinai Medical Center. 'In a single day, we performed multiple Trilogy cases, including as mentioned our first ARTIST case as well as implanting Trilogy in a patient with LVAD-related AR disease who was enrolled into the JENAVAD Registry. These experiences highlight just how much demand exists for less invasive solutions in this complex and undertreated population; it's a glimpse into how the Trilogy valve could reshape care for patients with AR.' 'ARTIST is a landmark study designed to answer a critical question of how to best treat patients with severe AR,' said Dr. Torsten Vahl, principal investigator of the ARTIST trial and interventional cardiologist at Columbia University Irving Medical Center. 'Building on ALIGN-AR, which established TAVR as a solution for high-risk AR patients, ARTIST has the potential to expand TAVR to a broader population of severe AR patients. It is also the first prospective head-to-head evaluation of TAVR versus surgery ever conducted in this patient population. The results will provide critical data to guide future treatment decisions in the structural heart community.' 'The launch and enrollment of ARTIST marks a defining moment for both JenaValve and the structural heart field,' said John Kilcoyne, Chief Executive Officer of JenaValve. 'ARTIST reflects our commitment to generating the highest level of clinical evidence as we work to bring a less invasive solution to a larger group of patients suffering from this challenging disease.' About JenaValveJenaValve Technology, Inc. is a medical device company focused on the design, development, and commercialization of innovative THV solutions for the treatment of patients suffering from heart valve disease. The Company's Trilogy THV System is a TAVR system designed to treat patients with symptomatic, severe AR, and symptomatic, severe aortic stenosis who are at high surgical risk. The Trilogy THV System received CE Mark approval, providing European physicians with the first TAVR device with true dual-disease treatment capabilities. In the US, the Trilogy THV System is limited to investigation use only. JenaValve is headquartered in Irvine, California, with additional locations in Leeds, United Kingdom, and Munich, Germany. JenaValve is backed by Bain Capital Life Sciences, Andera Partners, Valiance Life Sciences, Rosetta Capital, Cormorant Asset Management, Legend Capital, NeoMed Management, RMM, VI Partners, Pictet Alternative Advisors SA, Qatar Investment Authority (QIA), Innovatus Capital Partners, and Peijia Medical Limited. US: CAUTION – Investigational device. Limited by Federal (or United States) law to investigational use. Additional information is available at JenaValve Contact:Daniel Sun dsun@
